Stock Events

Stock Events

Cognetivity Neurosciences 

$0
3
+$0+0% Tuesday 21:00

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
1,000
Avg. Volume
0
Mkt Cap
8,955.6
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

16DecExpected
Q3 2020
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q2 2022
Q3 2022
-0.08
-0.06
-0.03
-0.01
Expected EPS
N/A
Actual EPS
-0.017

Financials

-16,615.52%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
67,638.66Revenue
-11.24MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CGNSF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly is a major pharmaceutical company that develops drugs for neurological diseases, including Alzheimer's, which competes with CGNSF's cognitive assessment technologies.
Biogen
BIIB
Mkt Cap26.03B
Biogen focuses on neurodegenerative diseases, including Alzheimer's disease treatments and diagnostics, directly competing with CGNSF's cognitive testing products.
Pfizer
PFE
Mkt Cap161.09B
Pfizer develops medications for various neurological conditions, which can be seen as alternatives to CGNSF's cognitive assessment tools.
Merck
MRK
Mkt Cap298.84B
Merck is involved in the development of treatments for Alzheimer's disease, competing in the same space as CGNSF's cognitive diagnostics.
Abbott Laboratories
ABT
Mkt Cap178.76B
Abbott Laboratories offers a range of healthcare solutions including diagnostics for neurological conditions, overlapping with CGNSF's market.
Novartis
NVS
Mkt Cap297.32B
Novartis provides healthcare solutions including neurological disease treatments, competing in the cognitive health space.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division, develops treatments for neurodegenerative diseases, competing with CGNSF's cognitive assessment tools.
AC Immune SA
ACIU
Mkt Cap280.9M
AC Immune focuses on Alzheimer's disease diagnostics and therapeutics, directly competing with CGNSF's cognitive assessment technologies.

About

Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that helps to detect the earliest signs of impairment by testing the performance of large areas of the brain to support the diagnosis of dementia; and offers OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Show more...
CEO
Dr. Sina Habibi
Employees
2500
Country
US
ISIN
CA19243C1005

Listings

OTC Link
US
CGNSF

0 Comments

Share your thoughts

FAQ

What is Cognetivity Neurosciences stock price today?▼
The current price of CGNSF is $0 USD — it has increased by +0% in the past 24 hours. Watch Cognetivity Neurosciences stock price performance more closely on the chart.
What is Cognetivity Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cognetivity Neurosciences stocks are traded under the ticker CGNSF.
Is Cognetivity Neurosciences stock price growing?▼
CGNSF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Cognetivity Neurosciences has showed a -94.74% decrease.
What is Cognetivity Neurosciences market cap?▼
Today Cognetivity Neurosciences has the market capitalization of 8,955.6
What were Cognetivity Neurosciences earnings last quarter?▼
CGNSF earnings for the last quarter are -0.02 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cognetivity Neurosciences revenue for the last year?▼
Cognetivity Neurosciences revenue for the last year amounts to 67,638.66 USD.
What is Cognetivity Neurosciences net income for the last year?▼
CGNSF net income for the last year is -11.24M USD.
How many employees does Cognetivity Neurosciences have?▼
As of April 11, 2026, the company has 2,500 employees.
In which sector is Cognetivity Neurosciences located?▼
Cognetivity Neurosciences operates in the Health Care sector.
When did Cognetivity Neurosciences complete a stock split?▼
Cognetivity Neurosciences has not had any recent stock splits.
Where is Cognetivity Neurosciences headquartered?▼
Cognetivity Neurosciences is headquartered in Vancouver, US.